Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361699 | 0.82 | TDP1 (0.44) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL2001345 | 0.79 | VCAM1 (0.51) | TDP1ALDH1A1VCAM1RAB9ATSHR | |
| SCHEMBL26928091 | 0.79 | TDP1 (0.42) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL1749233 | 0.79 | VCAM1 (0.47) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL9016834 | 0.79 | TDP1 (0.44) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL7550938 | 0.76 | VCAM1 (0.47) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL2416493 | 0.76 | ATM (0.42) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL938956 | 0.76 | TDP1 (0.48) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL1850626 | 0.75 | ALDH1A1 (0.47) | TDP1ATMALDH1A1HIF1AVCAM1 | |
| SCHEMBL1462237 | 0.75 | TRPV4 (0.39) | ALDH1A1HPGDMAPTCUL4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536642-A1 | HETEROCYCLIC COMPOUNDS AS PI3KA INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239846-A1 | HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239846-A1 | HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2649052-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309738-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | TDP1 1871/4885ATM 4243/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.